CTOs on the Move


 
We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.alumis.com
  • 611 Gateway Boulevard Suite 820
    South San Francisco, CA USA 94080
  • Phone: 650.231.6625

Executives

Name Title Contact Details

Similar Companies

Ariana Pharma

Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.

Stallergenes

Stallergenes is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Transcept Pharmaceuticals, Inc.

Transcept Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Biofourmis

Biofourmis is a fast-growing global health IT start-up founded in Singapore that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. The company discovers, develops and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized artificial intelligence (AI)-powered health analytics platform that predicts clinical exacerbation days in advance before a critical event. Biovitals™ is the backbone of the company`s Digital Therapeutics product pipeline, which spans a number of therapeutic areas and disease states, including heart failure, acute coronary syndrome, COPD and chronic pain.

Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.